Outside US, Novartis Licenses First Ophthalmology Gene Therapy – Drug Discovery & Development
Drug Discovery & Development |
Outside US, Novartis Licenses First Ophthalmology Gene Therapy
Drug Discovery & Development Novartis announced a licensing agreement with Spark Therapeutics covering development, registration and commercialization rights to voretigene neparvovec in markets outside the US. Voretigene neparvovec, known as LUXTURNA (voretigene neparvovec-rzyl … Spark Therapeutics: What Does The Recent Novartis Partnership Foretell? |
